<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549847</url>
  </required_header>
  <id_info>
    <org_study_id>CAR-PIR.11.01</org_study_id>
    <nct_id>NCT01549847</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome</brief_title>
  <official_title>A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Therapeutic Effect of the Association of L-carnitine and Piracetam as an Adjuvant Therapy in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biolab Sanus Farmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biolab Sanus Farmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This protocol aims to assess of L-carnitine and piracetam to relieve weakness, muscle fatigue&#xD;
      and muscle pain in patients with Postpoliomyelitis Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not approved by Health Surveillance Agency&#xD;
  </why_stopped>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Muscle Weakness</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in fatigue</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in muscle pain</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in daytime sleepiness</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in daily function</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in depressive mood</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxidative capacity in skeletal muscle</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Postpoliomyelitis Syndrome</condition>
  <arm_group>
    <arm_group_label>L-carnitine and piracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-carnitine and piracetam</intervention_name>
    <description>L-carnitine/piracetam (990mg/810mg) PO BID</description>
    <arm_group_label>L-carnitine and piracetam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo PO BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Postpoliomyelitis Syndrome diagnosis confirmed over a year;&#xD;
&#xD;
          -  Electromyography test compatible with poliomyelitis;&#xD;
&#xD;
          -  Preserved ability to swallow medication;&#xD;
&#xD;
          -  Oral communication ability preserved;&#xD;
&#xD;
          -  Preserved ability to perform pedaling test in at least one lower limb affected by&#xD;
             Postpoliomyelitis Syndrome;&#xD;
&#xD;
          -  Ability to understand information about the study and to document the decision about&#xD;
             participating in the trial by signing the Informed Consent Form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of intolerance to L-carnitine or piracetam;&#xD;
&#xD;
          -  Treatment with L-carnitine during the past 3 months;&#xD;
&#xD;
          -  Treatment with piracetam or any other nootropics pyrrolidone derivatives, during the&#xD;
             past three months;&#xD;
&#xD;
          -  Anemia (hemoglobin reference range - men 13 to 17 g/dL and women 12 to 15 g/dL);&#xD;
&#xD;
          -  High level of glycated hemoglobin (&gt; 7.0%);&#xD;
&#xD;
          -  Electrolyte imbalance (hypokalaemia - reference potassium concentration range: 3.5 to&#xD;
             5.6 mmol / L);&#xD;
&#xD;
          -  Renal failure (creatinine reference range: 0.70 to 1.50 mg/dL);&#xD;
&#xD;
          -  Urinary tract infection;&#xD;
&#xD;
          -  Thyroid dysfunction (reference range: free T4: 0.54 to 0.67 mg/dL and TSH reference&#xD;
             range: 0.5 to 5.5 μUI/mL) or usual treatment with thyroid hormone supplementation;&#xD;
&#xD;
          -  Cardiomyopathy;&#xD;
&#xD;
          -  Uncontrolled hypertension;&#xD;
&#xD;
          -  Known or suspected autoimmune disease;&#xD;
&#xD;
          -  Confirmed pregnancy, or plans to get pregnant during the trial;&#xD;
&#xD;
          -  Depression or bipolar affective disorders with moderate to severe episodes within the&#xD;
             last twelve months;&#xD;
&#xD;
          -  Insulin-dependent diabetes mellitus;&#xD;
&#xD;
          -  Treatment with anticoagulant drugs over two weeks (including non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs), warfarin, phenprocoumon, heparin);&#xD;
&#xD;
          -  Usual cocaine or alcohol use;&#xD;
&#xD;
          -  Any other condition judged by the investigator as a possibility to interfere on the&#xD;
             participant's decision to be part of the study or to accomplish investigation&#xD;
             procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Acary Souza Bulle Oliveira, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNIFESP</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>March 7, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpoliomyelitis Syndrome</keyword>
  <keyword>Piracetam</keyword>
  <keyword>L-Carnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpoliomyelitis Syndrome</mesh_term>
    <mesh_term>Myalgia</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

